The Recall Desk
SevereFDA (Drugs)·D-0311-2019·Announced 2018-12-19

Mylan Recalls Amlodipine and Valsartan Tablets Due to NDEA Impurity

Mylan Pharmaceuticals is recalling Amlodipine and Valsartan tablets because FDA testing found the impurity N-nitrosodiethylamine (NDEA) in the active ingredient.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. The presence of NDEA, a potential carcinogen, in a prescription drug elevates the severity to Severe (4) per the rubric for significant injury/property-damage reports or high-risk contamination.

Plain-English summary

Mylan Pharmaceuticals Inc. is recalling Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottles. The recall involves 23,478 bottles of the prescription medication, which was distributed throughout the United States. The specific lot number is 3066051, with an expiration date of 3/2019.

The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. FDA laboratory testing confirmed the presence of N-nitrosodiethylamine (NDEA), a known impurity, in the active pharmaceutical ingredient (API) used to manufacture the product. NDEA is a potential carcinogen.

Consumers and healthcare providers should stop using the affected medication and contact their healthcare provider for alternative treatment options. The product should be returned to the pharmacy or disposed of according to local regulations.

The recalled product

Product
AMLODIPINE AND VALSARTAN (AMLODIPINE AND VALSARTAN)
Brand
AMLODIPINE AND VALSARTAN
Manufacturer
Mylan Pharmaceuticals Inc.
Category
Drug — Prescription Medication
Hazard
Affected units
23,478

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # 3066051
  • exp. date 3/2019

UPCs (4)

  • 0303781722933
  • 0303781723930
  • 0303781721936
  • 0303781724937

Distribution

Distribution scope not specified by the agency.

Part of a larger recall action

This product is one of 8 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 8 products in this recall →

Related recalls

Same brand · AMLODIPINE AND VALSARTAN

Same manufacturer · Mylan Pharmaceuticals Inc.

See all →

Same hazard · impurity

See all →